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ORIGINAL ARTICLE
Decreased Fibrogenesis After Treatment with Pirfenidone in
a Newly Developed Mouse Model of Intestinal Fibrosis
Remo Meier,* Christian Lutz,* Jesus Cosín-Roger, MD,*,† Stefania Fagagnini, MD,* Gabi Bollmann,*
Anouk Hünerwadel,* Celine Mamie,* Silvia Lang,* Alexander Tchouboukov, PhD,‡ Franz E. Weber, MD,‡
Achim Weber, MD, PhD,§ Gerhard Rogler, MD, PhD,* and Martin Hausmann, PhD*
Background: Fibrosis as a common problem in patients with Crohn’s disease is a result of an imbalance toward excessive tissue repair. At present, there is
no speciﬁc treatment option. Pirfenidone is approved for the treatment of idiopathic pulmonary ﬁbrosis with both antiﬁbrotic and anti-inﬂammatory effects.
We subsequently investigated the impact of pirfenidone treatment on development of ﬁbrosis in a new mouse model of intestinal ﬁbrosis.
Methods: Small bowel resections from donor mice were transplanted subcutaneously into the neck of recipients. Animals received either pirfenidone
(100 mg/kg, three times daily, orally) or vehicle.
Results: After administration of pirfenidone, a signiﬁcantly decreased collagen layer thickness was revealed as compared to vehicle (9.7 6 1.0 versus
13.5 6 1.5 mm, respectively, **P , 0.001). Transforming growth factor–b and matrix metalloproteinase–9 were signiﬁcantly decreased after treatment
with pirfenidone as conﬁrmed by real-time PCR (0.426 0.13 versus 1.006 0.21 and 0.466 0.24 versus 1.006 0.62 mRNA expression level relative to
GAPDH, respectively, *P , 0.05). Signiﬁcantly decreased transforming growth factor–b after administration of pirfenidone was conﬁrmed by Western
blotting.
Conclusion: In our mouse model, intestinal ﬁbrosis can be reliably induced and is developed within 7 days. Pirfenidone partially prevented the
development of ﬁbrosis, making it a potential treatment option against Crohn’s disease–associated ﬁbrosis.
(Inﬂamm Bowel Dis 2016;22:569–582)
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S evere and persistent mucosal tissue damage is a main featureof inﬂammatory bowel disease (IBD). Tissue injury triggers
an important inﬂammatory response, which in turn leads to the
initiation of a reparatory process.1–3 Rapid and adequate healing
is essential to reduce the exposure of the underlying tissue to
luminal antigens and potential pathogens and to restore a tight
barrier. Furthermore, adequate wound healing physiologically is
the result of an exquisite balance between multiple proﬁbrotic
and antiﬁbrotic stimuli on extracellular matrix–producing
cells.4–7 The primary cellular mediator of ﬁbrosis is the myoﬁ-
broblast, which can be generated from several sources.8 Exces-
sive tissue repair promotes ﬁbrosis and impairs gastrointestinal
function and is a common clinical problem in patients with
Crohn’s disease (CD).
Fibrosis is increasingly being recognized as an important
cause of morbidity and mortality in many chronic inﬂammatory
diseases. The pathogenesis of ﬁbrosis in patients with CD,
however, is still poorly understood. Intestinal ﬁbrosis leads to
stricture formation in 30% to 50% of patients with CD9,10 and
requires surgery in approximately 80% of strictured patients.9
Administration of potent anti-inﬂammatory agents effec-
tively treats inﬂammatory ﬂares but may not alter the course of
intestinal ﬁbrosis and fail to prevent the formation of stric-
tures.11,12 Despite earlier initiation of immunosuppressants or bio-
logicals during the course of CD, the percentage of patients
requiring intestinal surgery due to the occurrence of stricturing
complications has only decreased slightly.13 Recently, it was dem-
onstrated that treating inﬂammation may not be sufﬁcient to pre-
vent the progression of ﬁbrosis. Furthermore, there is evidence
that intestinal ﬁbrogenesis after being once initiated is—at least to
some extent—a self-perpetuating process.14 Therefore, many ex-
perts point to the unmet clinical need of a medical treatment to
prevent or inhibit ﬁbrogenesis/ﬁbrosis.
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The clinical investigation of intestinal ﬁbrosis is conﬁned to
the limited amount of biological material available from patients.
Establishing an animal model that reﬂects the development of
intestinal ﬁbrosis in humans is therefore regarded to be a pre-
requisite for the development of drugs targeted at intestinal ﬁbrosis.
To develop such an animal model, we adopted a rat airway
transplant model of bronchiolitis obliterans.15 Recently, we
described a new model of intestinal ﬁbrosis by performing a hetero-
topic transplantation of small bowel resections in rats. The loss of
intestinal epithelial morphology, exaggerated collagen deposition,
expression of proﬁbrotic mediators, and progressive luminal wall
thickening culminating in a veritable ﬁbrotic occlusion of the intes-
tinal lumen faithfully reﬂect the histologic and molecular features
of human intestinal ﬁbrosis. The simplicity and efﬁciency of this
model may greatly aid the study of the pathogenesis of intestinal
ﬁbrosis and the development of suitable therapeutics to prevent and
treat intestinal ﬁbrosis16. However, to allow the study of mechanis-
tic aspects of intestinal ﬁbrosis in knock-out animals and to allow
drug treatment experiments with lower amounts of substance, the
model had to be transferred into mice.
In this study, we describe the successful establishment of
a mouse model of intestinal ﬁbrosis in which we investigated
pirfenidone as a possible candidate for an antiﬁbrotic treatment in
intestinal ﬁbrosis.
Pirfenidone (Esbriet; Hoffmann-La Roche AG, Basel,
Switzerland) is an orally bioavailable small molecule developed by
InterMune Inc. (Brisbane, CA). It exhibits well-documented anti-
ﬁbrotic and anti-inﬂammatory properties in a variety of animal and
in vitro models in different organs, including ﬁbrosis of the lung,17
kidneys,18 heart,19 liver,20 and skin.21 The exact molecular mechanism
of action so far is unknown.22 Pirfenidone inﬂuences signiﬁcantly the
production of various cytokines and growth factors, with the most
commonly reported effect being a reduction of transforming growth
factor–b (TGF-b).19,20,23 Others reported decreased interleukin (IL)-
1b, IL-6, and monocyte chemotactic protein (MCP)-1 protein after
treatment with pirfenidone shown in supernatants of lung homoge-
nates in the bleomycin-induced murine model of pulmonary ﬁbrosis.23
Decreased transcript levels of the matrix metalloproteinase (MMP)-2
and tissue inhibitor of metalloproteinase (TIMP)-1 after treatment
with pirfenidone were shown in a dimethylnitrosamine-induced rat
model of liver ﬁbrosis.20 Decreased transcript levels of collagens I and
III after treatment with pirfenidone were shown in primary cultures of
human myometrial and leiomyoma smooth muscle cells.24
A meta-analysis of progression-free survival time in three
phase III clinical trials of pirfenidone in patients with idiopathic
pulmonary ﬁbrosis (IPF) reported a signiﬁcant overall treatment
beneﬁt.25 It was approved in Japan as Pirespa in 2008. It was
approved in China and in Europe for the treatment of IPF in
2011 and in October 2014 in the United States by the Food and
Drug Administration.
In this study, we describe our rapid and reliable animal
model of intestinal ﬁbrosis and show that pirfenidone also
prevents intestinal ﬁbrosis, indicating its potential as treatment
option for stricturing CD.
MATERIALS AND METHODS
Animals
Female B6-Tg (UBC-GFP) 30Scha/J donor mice (GFP-Tg)
weighing 20g were bred locally. C57BL/6J-Crl1 mice (C57BL/6)
were obtained from Charles River. BALB/c mice (BALB/c) were
obtained from Jackson Laboratories. The animals received
standard laboratory mouse food and water ad libitum. They were
housed under speciﬁc pathogen-free conditions in individually
ventilated cages. The experimental protocol was approved by the
local Animal Care Committee of the University of Zurich
(registration number: ZH183/2014).
Heterotopic Intestinal Transplant Model
The heterotopic mouse intestinal transplant model is an
adaption of the heterotopic transplantation model of intestinal
ﬁbrosis in rats, which has been previously described in detail.16 In
short, donor small bowel resections were extracted and transplanted
subcutaneously into the neck of recipient animals. Transplantation
was performed between mice of the same gender. All procedures
were performed using a sterile nontouch technique. Donor mice
were killed by neck dislocation. After an initial anterior midline
incision, the abdomen was opened completely to avoid contamina-
tion of the inner organs with hair. The small bowel was then
exposed and carefully unfolded by cutting mesentery where neces-
sary. From the small bowel proximal to the cecum, a segment of 6
cm was excised. The resection was then ﬂushed with 5 mL of 0.9%
NaCl to remove stool and divided into 6 equal 10-mm parts. Re-
sections were kept moist with 0.9% NaCl solution, whereas the
recipient animals were prepared for transplantation (see Fig. A,
Supplemental Digital Content 1, http://links.lww.com/IBD/B209).
Recipient animals were anesthetized with isoﬂurane, and ocular
lubricant was applied (Vitamine A Blache Augensalbe 5g
#109778). A small area of the back was shaved to avoid contami-
nation with hair. Two subcutaneous pouches were prepared through
a small incision perpendicular to the body axis on either side of the
neck (Fig. B, Supplemental Digital Content 1, http://links.lww.com/
IBD/B209). A small bowel resection was implanted into each of the
subcutaneous pockets (Fig. C, Supplemental Digital Content 1,
http://links.lww.com/IBD/B209), and the skin was closed using
vicryl 5-0 stitches or a 3M Precise Vista Skin Stapler (Fig. D,
Supplemental Digital Content 1, http://links.lww.com/IBD/B209).
A single dose of cefazolin (Kefzol, Teva Pharma AG, Basel, Swit-
zerland; 1g diluted in 2.5-mL aqua dest) was applied intraperitone-
ally as infection prophylaxis. The time interval between graft
resection and subsequent implantation was less than 15 minutes.
No anesthesia-related recipient death, posttransplantation recipient
death, or evidence of infection was observed in any of the animals.
Recipient mice were killed by neck dislocation. Intestinal
grafts were explanted up to 21 days after transplantation. Numerous
blood vessels stretched toward the transplanted tissue (see Fig. H,
Supplemental Digital Content 1, http://links.lww.com/IBD/B209)
where they formed a dense network (see Fig. I, Supplemental
Digital Content 1, http://links.lww.com/IBD/B209). At
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explantation, each graft was divided into 3 equal segments. One
segment was ﬁxed in 4% formalin and prepared for histopatholog-
ical assessment. The other segments were snap frozen in liquid
nitrogen and stored at 2808C until RNA extraction or lysis in
MPER buffer.
Pirfenidone Preparation and Application
Esbriet tablets (276 mg, InterMune Inc., now part of the F.
Hoffmann-La Roche AG) were dissolved in 14-mL sterile water to
a pirfenidone concentration of 20 mg/mL. Pirfenidone was orally
administered to recipient mice by oral gavage using a gastric tube.
Pirfenidone (100 mL ¼ 100 mg/kg) was administered 3 times a day
orally (7:00–10:00, 13:00–16:00, 19:00–22:00) for 6 days after
transplantation. Sterile water was used as vehicle control. For
in vitro experiments, Pirfenidone was dissolved in methanol.
Stent Insertion
A cobalt chromium coronary stent coated with epoxy resin
(Invatec Skylor, Roncadelle, Italy) measuring 10 mm in length and 2
mm in diameter was used. After isolating a section of intestine from
a C57BL/6 donor mouse, a stent was inserted into the open lumen of
the resection before then being implanted in the subcutaneous neck
pouch of a B6 recipient mouse. The graft was explanted at day 7 and
embedded in epoxy resin for histological analysis.
Paragon and Giemsa Staining
The specimens were prepared with a sequential water
substitution process, then placed in xylene for 72 hours, and
inﬁltrated by placing them in methyl methacrylate (MMA) for 72
hours (Fluka 64,200) followed by 3 days in 100-mL MMA + 2-g
dibenzoylperoxid (Fluka 38,581) at 4 C8. Samples were embedded
by placing them in 100-mL MMA + 3-g dibenzoylperoxid + 10-
mL plastoid N or dibutyl phthalate (Merck 800 19.25) and allowing
polymerization to occur at 37 C8 in an incubator. After embedding,
the specimens were sectioned by a diamond band saw (Exakt 300P)
glued to a support and sectioned again, so that a 200-mm thick
sample from the middle was attached to the support. The thickness
of this sample was further reduced to 40 to 60 mm by a grinding
machine (Exakt 420 CS). To visualize tissues, the samples were
Paragon and Giemsa stained. Digital images were taken and pro-
cessed with an image program (Adobes Photoshop CS3).
Immunohistochemistry
TGF-b1 was stained with a rabbit polyclonal antibody from
Santa Cruz Biotechnology Inc. (Dallas, TX) (#sc-146, dilution 1:200,
immunostainer Leica Bond III Stainer, pretreatment: Bond Epitope
Retrieval Buffer 2 for 20 minutes, detections kit: Bond Polymer
Reﬁne Detections Kit, all reagents from Bond Leica). The sections
were examined with the Imager Z2 microscope (Carl Zeiss AG,
Oberkochen, Germany) and the software AxioVision (Zeiss). Sirius
red–stained slides were analyzed in bright ﬁeld using a polarization
ﬁlter. Under polarized light, sirius red–stained collagen assumes a pal-
ette of colors ranging from green to red as a sign for ﬁbrotic process
maturation. Collagen layer thickness was determined by an
investigator blinded to experiment. Thickness was calculated from
at least 8 places in representative areas at 10-fold magniﬁcation.
TaqMan Gene Expression Assays
a-SMA Mm00725412_s1, BCL-XL Mm00437783_m1,
MMP-9 Mm00442991_m1, MMP-2 Mm00439498_m1, TIMP-1
Mm00441818_m1, TGF-b1 Mm01178820_m1, lysyl oxidase–
like 2 (LOXL-2) Mm00804740_m1, collagen type I alpha 1
(Col1a1) Mm00801666_g1, collagen type III alpha 1 (Col3a1)
Mm01254476_m1, and GAPDH 4352339E. The relative cDNA
concentration for the gene of interest was calculated using the
ddCt method.
Cell Viability Assay
Primary murine colonic ﬁbroblasts were isolated as described
earlier.26 Five thousand colonic ﬁbroblasts per well were grown in
triplicate cultures in 96 well plates. The ﬁnal volume of culture
medium in each well was 100 mL. Cells were starved 24 hours
before stimulation. Cells were stimulated with 2 ng/mL TGF-
b and 0-, 0.1-, 0.5-, and 1-mg/ml pirfenidone for 24 hours. The
colorimetric assay (WST-8–based; Dojindo Molecular Technologies,
Rockville, MD) for quantiﬁcation of cell viability was performed
according the manufacturer’s protocol. Brieﬂy, 10 mL cell counting
kit (CCK)-8 solution was added to detect viable cells. The absorption
was measured 4 hours after addition of the CCK-8 labeling at
450 nm using a microplate reader.
Wounding Assay
Colonic ﬁbroblasts were seeded in culture inserts (#80209,
width of cell-free gap, 500 mm 6 50 mm, ibidi). Conﬂuent mono-
layers of cells were starved 24 hours before the wounding assay.
The culture inserts were removed and cells were stimulated with
2-ng/mL TGF-b and 1-mg/ml pirfenidone. Wound closure was
documented at t ¼ 0, 24, and 48 hours with the Axiovert micro-
scope (Zeiss) at 5-fold magniﬁcation and the Powershot camera
(Canon, Tokyo, Japan).
Western Blot
Equal amounts of protein were loaded onto SDS/PAGE
gels. Western blots were performed using monoclonal rabbit
anti-mouse TGF-b (#3711S, Bioconcept, 1:1000), polyclonal
rabbit anti-mouse b-actin (#4970, 13E5; Cell Signaling Tech-
nology, Cambridge, MA; 1:2000), and the horseradish peroxi-
dase–conjugated secondary antibody goat anti-rabbit (#sc-2004;
Santa Cruz, 1:2000), respectively. Focal adhesion kinase (FAK)
protein detection was performed with speciﬁc antibodies to FAK
(#3285; Cell Signaling, 1:1000) and phosphorylated tyrosine
397 of FAK (#3283; Cell Signaling, 1:1000), and incubation
with peroxidase-conjugated secondary antibody goat anti-
rabbit (#sc-2004; Santa Cruz, 1:2000). Luminescence of West-
ern blots was quantiﬁed densitometrically with ImageJ.
Statistical Analysis
Statistical analysis for collagen layer thickness was per-
formed using Kruskal–Wallis one-way analysis of variance on
Inﬂamm Bowel Dis  Volume 22, Number 3, March 2016 Decreased Fibrogenesis After Pirfenidone Treatment
www.ibdjournal.org | 571
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
ranks, all-pairwise multiple comparison procedures (Tukey test).
Statistical analysis for qPCR was performed using Kruskal–
Wallis one-way analysis of variance on ranks, all-pairwise
multiple comparison procedures (Holm–Sidak method), or
unpaired t-test when was appropriated. Differences were consid-
ered signiﬁcant at a P value of, 0.05 (*) and highly signiﬁcant at
a P value of , 0.01 (**) and P value of , 0.001 (***).
Ethical Considerations
The experimental protocol was approved by the local
Animal Care Committee of the University of Zurich (registration
number: ZH183/2014).
RESULTS
Establishment of a Fast and Reliable
Heterotopic Transplantation Model of
Intestinal Fibrosis
To determine the relevance of the genetic background of
donor and recipient in our heterotopic transplantation model of
intestinal ﬁbrosis, BALB/c mice were used as donors for allogeneic
transplantation, whereas C57BL/6 were used as donors for iso-
geneic transplantation into C57BL/6 recipients. Eight isogeneic
transplants (C57BL/6 into C57BL/6 mice) and 16 allogeneic
transplants (BALB/c into C57BL/6 mice) were performed. Grafts
were explanted up to 21 days after transplantation. Macroscopi-
cally, a reduction in the graft length appeared. Histologically
evaluable tissue was recovered from all but 4 animals.
In EvG-stained histological cross sections, freshly isolated
small intestine was characterized by an open lumen and distinctive
epithelial crypts (Fig. 1A and C). At day 21 after transplantation,
the lumen of intestinal grafts was obstructed by granulation tissue
and ﬁbrotic material (Fig. 1B and E). Intestinal grafts already had
lost their typical crypt structure at day 2 after transplantation. At
day 5 after transplantation, the loss of crypt structures was complete
and a partial occlusion of the lumen was observed (Fig. 1D). At day
14, luminal occlusion was complete. Epithelial structure was lost in
heterotopic intestinal of both isografts and allografts.
Collagen production and deposition in the intestinal trans-
plants were determined by EvG staining in transmission light. The
collagen layer thickness in harvested grafts was signiﬁcantly
increased after 7 and 21 days in a time-dependent manner (P ,
0.05, Fig. 1F). To conﬁrm the time-dependent increase in collagen
and to differentiate between long-chain and short-chain collagen,
we performed sirius red staining (see Fig. 2, Supplemental Digital
Content 2, http://links.lww.com/IBD/B210). Freshly isolated
intestinal samples showed mostly long-chained collagen (red
stain) adjacent to the submucosa (see Fig. B, Supplemental Digital
Content 2, http://links.lww.com/IBD/B210). The presence of
short-chained collagen (yellow stain) increased continuously with
time in the submucosa and in the luminal occlusion after trans-
plantation (see Fig. D–N, Supplemental Digital Content 2, http://
links.lww.com/IBD/B210). The loss of epithelial structure and
luminal occlusion was observed irrespective of the genotype of
donor and recipient mice.
As in the transplant model of bronchial ﬁbrosis, the lumen
of the transplanted bronchus/trachea does not collapse to the
cartilage present, we investigated whether an open gut lumen
would inﬂuence ﬁbrosis in our intestinal transplant model.
Subsequently, a coronary stent was inserted into a graft before
transplantation in an attempt to preserve the gut lumen. C57BL/6
mice were used as both donor and recipient. After explantation at
day 7, we observed a shortened graft and a pronounced inﬁltration
of cells into the lumen, causing an almost complete occlusion (see
Fig. 3, Supplemental Digital Content 3, http://links.lww.com/
IBD/B211). Thus, the ﬁbrotic model is effective irrespective of
a preserved or collapsed lumen of the transplant.
Mediators of Fibrosis in the Heterotopic
Transplant Model of Intestinal Fibrosis
To further substantiate that the observed changes represent
ﬁbrotic changes, expression of TGF-b was analyzed. Both BALB/c
and C57BL/6 were used as donors for allogeneic and isogeneic
transplantation. C57BL/6 mice were used as recipients. TGF-
b was detected by immunohistochemistry along the crypt villus axis
in mouse intestinal epithelial cells in freshly isolated intestinal sam-
ples (Fig. 2A, C and D). No TGF-b was detected in the lamina
propria. Intense staining for TGF was found in the luminal occlusion
in allografts from day 5 to day 21 (Fig. 2E, F). Intense staining for
TGF was also found in heterotopic intestinal isografts (not shown).
Host Cells Inﬁltrate the Intestinal Graft
The presence of endogenous GFP in GFP-Tg recipient
mice allowed for a genotype-speciﬁc staining to be performed.
We could thus determine the origin of the lumen-obstructing
cells. We performed isogeneic transplantation using C57BL/6
mice as donors and GFP-Tg mice as recipient. As expected, the
freshly isolated intestinal resections from C57BL/6 mice are
negative for GFP staining (Fig. 3A). An increase in inﬁltration
of stained GFP cells ensued in a time-dependent manner. Ini-
tially, red-stained cells were visible exclusively in the submu-
cosa and seemed to accumulate along the collagen layer (Fig.
3B). Subsequent time points showed progressive inﬁltration
along the crypts and into the lumen (Fig. 3C–F). The collagen
layer was free of red-stained cells.
Typical Fibrosis Mediators Are Decreased In
Vitro in Colonic Fibroblasts After Treatment
with Pirfenidone Treatment
We next investigated whether pirfenidone as an agent
approved for the therapy and prevention of progress in IPF would
be effective in vitro in colonic ﬁbroblasts. TGF-b of 2 ng/mL sig-
niﬁcantly increased both MMP-9 and COL1A1 mRNA expression
(P , 0.05 and P , 0.01, respectively, n ¼ 2, see Fig. 4, Supple-
mental Digital Content 4, http://links.lww.com/IBD/B212) and was
used for further stimulations. To determine effects of pirfenidone
and TGF-b on the viability of colonic ﬁbroblasts, we used a CCK-8
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colorimetric assay for the quantiﬁcation of cell viability (see Fig. 5,
Supplemental Digital Content 5, http://links.lww.com/IBD/B213).
Colonic ﬁbroblasts showed an increase in cell viability after admin-
istration of pirfenidone in a dose-dependent manner (n ¼ 5 each
column). Cell viability was also signiﬁcantly increased on TGF-
b stimulation (162% 6 8%, n ¼ 5) as compared with vehicle (set
to 100%, n ¼ 5, P , 0.001, see Fig. 5, Supplemental Digital
Content 5, http://links.lww.com/IBD/B213) but did not further
increase after treatment with additional pirfenidone.
In the absence of TGF-b stimulation, COL1A1 mRNA
expression was signiﬁcantly decreased in colonic ﬁbroblasts after
administration of 1-mg/mL pirfenidone (n ¼ 5 each column, P ,
0.001, Fig. 4A), and a-SMA mRNA expression was signiﬁcantly
decreased in a dose-dependent manner (P , 0.05; P , 0.01),
whereas no changes in TGF-b expression were detected after
treatment with pirfenidone. After additional TGF-b stimulation,
a signiﬁcantly decreased TGF-b, COL1A1, MMP-9, and a-SMA
mRNA expression was detected after administration of pirfeni-
done in a dose-dependent manner compared with vehicle (n ¼ 5
each column, P , 0.01, P , 0.001, Fig. 4A). In contrast, pro-
survival BCL-XL mRNA expression was signiﬁcantly increased
after administration of 1-mg/mL pirfenidone independent of TGF-
b stimulation (n ¼ 5 each column, P , 0.001, Fig. 4A).
Tyrosine phosphorylation of p125 FAK is a central
regulator of cell migration. Western blotting revealed unchanged
expression of total FAK after treatment with pirfenidone
(Fig. 4B, representative for 4 experiments). A quantiﬁcation of
FAK phosphorylation was also performed and revealed signiﬁ-
cantly increased pFAK after administration of pirfenidone in
a dose-dependent manner independent of TGF-b stimulation
FIGURE 1. Increased collagen layer thickness in heterotopic intestinal grafts. Histologic cross sections of freshly isolated small intestine (A and C)
and explanted at days 5 (D) and 21 (B and E) after transplantation. EvG staining of mouse small heterotopic intestinal grafts revealed an increase of
collagen deposition in a time-dependent manner. (F) EvG staining revealed signiﬁcantly increased collagen layer thickness (*P , 0.05, Kruskal–
Wallis one-way analysis of variance on ranks, all-pairwise multiple comparison procedures (Tukey test), n ¼ 9 for each column). BALB/c mice were
used as donors for allogeneic transplantation; B6 were used as donors for isogeneic transplantation. B6 were used as recipients.
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(n ¼ 4 each column, P , 0.001, Fig. 4B). Accordingly, gain of
migratory potential of colonic ﬁbroblasts could be conﬁrmed in
a wounding assay. In line with this, the wounding assay revealed
an advanced wound closure after 24 and 48 hours after treatment
with pirfenidone independent of TGF-b stimulation (see Fig. 6,
Supplemental Digital Content 6, http://links.lww.com/IBD/
B214, representative for 2 experiments).
Development of Intestinal Fibrosis Is Partially
Prevented in Grafts After Administration
of Pirfenidone
We next investigated whether pirfenidone would also be
effective in our model of intestinal ﬁbrosis. We performed
isogeneic transplantation using GFP-Tg mice as donors and
C57BL/6 mice as recipient. Body weight remained unchanged
after treatment with pirfenidone (n ¼ 7 mice) compared with
vehicle (n ¼ 8 mice, see Fig. 4, Supplemental Digital Content
4, http://links.lww.com/IBD/B212). Interestingly, a trend to
lower body weight was seen after administration of pirfeni-
done, which may reﬂect dizziness triggered by pirfenidone as
reported by others. We determined collagen production and
deposition in the intestinal transplants by EvG staining in trans-
mission light and under polarizing light (Fig. 5). The collagen
layer thickness in harvested grafts from mice after treatment
with pirfenidone was signiﬁcantly decreased in comparison to
the collagen layer thickness in grafts from vehicle treated mice
(P , 0.001 for data obtained by transmission light and P ,
0.05 for data obtained by polarized light microscopy, n ¼ 12–
14 grafts as indicated).
TGF-b1 Is Expression Signiﬁcantly Decreased
in Grafts After Administration of Pirfenidone
In the grafts, a signiﬁcantly decreased TGF-b mRNA
expression after pirfenidone treatment compared with vehicle
FIGURE 2. Increased TGF-b in heterotopic intestinal grafts. Immunohistochemistry for TGF-b of mouse small intestine allografts. Histologic cross
sections of freshly isolated small intestine (A, C, and D) and explanted at days 5 (E) and 21 (B and F) after transplantation. Transmitted light
microscopy. In freshly isolated intestinal samples, TGF-b (brown) was increased along the crypt villus axis in mouse intestinal epithelial cells (D).
Data revealed increased expression of TGF-b, a potent mediator of ﬁbrosis. Each image is representative for 2 samples investigated. BALB/c mice
were used as donors for allogeneic transplantation; B6 were used as donors for isogeneic transplantation. B6 were used as recipients.
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(0.42 6 0.13, n ¼ 13 versus 1.00 6 0.21, n ¼ 15, respectively, P
, 0.05, Fig. 6A) was detected by qPCR. A quantiﬁcation of TGF-
b expression by Western blotting of graft lysates was also per-
formed and revealed a signiﬁcant decrease in grafts from mice
after administration of pirfenidone compared with grafts from
mice on vehicle (P , 0.05, n ¼ 3 for each column, Fig. 6B). A
pronounced TGF-b staining on vehicle as compared to pirfeni-
done 6 days after transplantation was detected (Fig. 6C). A sig-
niﬁcantly decreased number of TGF-b–positive cells after
treatment with pirfenidone as compared to vehicle (P , 0.05,
FIGURE 3. Host cells progressively inﬁltrate the intestinal graft. Immunohistochemistry of lumen-obstructing cells of recipient origin. Freshly isolated
intestinal resections are negative for GFP (A). Increase in inﬁltration at days 1 (B), 2 (C), 5 (D), 7 (E), and 14 (F) in a time-dependent manner.
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FIGURE 4. TGF-b1 mRNA is signiﬁcantly decreased after administration of pirfenidone in intestinal ﬁbroblasts in vitro. Increased pFAK after
administration of pirfenidone compared to control. TGF-b, COL1A1, MMP-9, and a-SMA mRNA expressions are decreased, and BCL-XL mRNA
expression is increased after treatment with pirfenidone compared to vehicle (*P , 0.05, **P , 0.01, ***P , 0.001, ##P , 0.01, ###P , 0.001, n¼ 5
each column, error bars ¼ SEM, A). Western blotting (left) and densitometric analysis (right) showed signiﬁcant increase in the ratio pFAK/total FAK
after treatment with pirfenidone (*P , 0.05, **P , 0.01, ***P , 0.001, ##P , 0.01, n ¼ 4, error bars ¼ SEM, B).
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FIGURE 5. Collagen layer thickness is signiﬁcantly decreased after administration of pirfenidone in grafts from the heterotopic transplantation
model. Sirius red staining. (A) Transmission light showed signiﬁcantly decreased collagen layer thickness after treatment with pirfenidone
compared to vehicle (**P , 0.001). (B) Polarizing light microscopy conﬁrmed signiﬁcantly decreased collagen layer thickness after treatment with
pirfenidone (*P , 0.05), n ¼ 12 to 14 as indicated. Thickness was calculated from at least 8 places in representative areas at 10-fold magniﬁcation
for each single graft. Mean value and SD are shown.
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FIGURE 6. TGF-b1 is signiﬁcantly decreased after administration of pirfenidone in grafts from the heterotopic transplantation model. (A)
Signiﬁcant decrease in TGF-b mRNA expression after treatment with pirfenidone compared to vehicle (*P , 0.05, n ¼ 13 and 15,
respectively). (B) Western blotting conﬁrmed signiﬁcant decrease in TGF-b after administration of pirfenidone (*P , 0.05, n ¼ 3 for each
column). Error bars ¼ SD. Grafts exhibited a pronounced TGF-b staining (3,3’-diaminobenzidine, brown) on vehicle compared with pirfe-
nidone. (C) Immunohistochemistry reveals a signiﬁcant decrease in TGF-b1–positive cells after treatment with pirfenidone. (D and E)
Number of TGF-b–positive cells (red crosses) was signiﬁcantly increased on vehicle (*P , 0.05, Kruskal–Wallis one-way analysis of variance
on ranks, all-pairwise multiple comparison procedures (Holm–Sidak method), D and E). Number of TGF-b–positive cells was normalized to
the number of total cells (nuclei labeled by yellow and red crosses).
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Fig. 6D, E) conﬁrmed the qPCR and Western blot data. TGF-
b was therefore shown to be decreased in the heterotopic intestinal
grafts after administration of pirfenidone.
pFAK Is Signiﬁcantly Increased in Grafts After
Treatment with Pirfenidone
Western blotting revealed increased phosphorylation of
FAK after administration of pirfenidone (Fig. 7A, n ¼ 4 each
group). A quantiﬁcation of FAK phosphorylation was also per-
formed and revealed signiﬁcantly increased pFAK after treatment
with pirfenidone (P , 0.01). Western blotting also revealed
unchanged expression of total FAK after administration of pirfe-
nidone. In line with in vitro experiments, a-SMA mRNA expres-
sion was signiﬁcantly decreased (n ¼ 9 each column, P , 0.05,
Fig. 7B), and prosurvival BCL-XL mRNA expression was signif-
icantly increased after treatment with pirfenidone (n ¼ 9 each
column, P , 0.05, Fig. 7B).
Matrix Degrading MMPs and
Proinﬂammatory Cytokines Are Decreased
After Administration of Pirfenidone
We determined the expression of tissue remodeling pro-
teases MMP-2, MMP-9, MMP-13, and the TIMP-1 in intestinal
transplants by real-time PCR. Grafts from mice treated with
pirfenidone showed a signiﬁcant decrease in MMP-9 mRNA
expression compared with vehicle (0.46 6 0.24 versus 1.00 6
0.62 mRNA expression level relative to GAPDH, P , 0.05, Fig.
8A). Similar, MMP-2, MMP-13, and TIMP-1 mRNA expressions
were decreased after treatment with pirfenidone compared with
vehicle (0.596 0.50 versus 1.006 0.68, 0.60 6 0.72 versus 1.00
6 1.01, and 0.42 6 0.43 versus 1.00 6 0.92 mRNA expression
level relative to GAPDH, respectively, not signiﬁcant, Fig. 8A).
Transplants from mice treated with pirfenidone also showed
a decrease in mRNA of proinﬂammatory cytokines IL-1b, IL-6,
and MCP-1 as compared to vehicle (0.42 6 0.43 versus 1.00 6
0.92, 0.52 6 0.38 versus 1.00 6 0.89, and 0.53 6 0.44 versus
1.00 6 0.88 mRNA expression level relative to GAPDH, respec-
tively, not signiﬁcant, Fig. 8B). LOXL-2 is a copper-dependent
matrix amine oxidase and a member of the lysyl oxidase enzyme
family. The function of this oxidase is the stabilization of collagen
ﬁbrils and ﬁbers in the extracellular matrix. Grafts from mice
treated with pirfenidone showed a decrease in mRNA of
LOXL-2 and also the major component of type I collagen
COL1A1 and COL3A1, frequently found in association with type
I collagen compared to vehicle (0.54 6 0.431 versus 1.00 6 0.67,
0.71 6 0.65 versus 1.00 6 0.87, and 0.57 6 0.59 versus 1.00 6
0.96 mRNA expression level relative to GAPDH, respectively,
not signiﬁcant, Fig. 8C).
DISCUSSION
In this study, we describe a new murine model of intestinal
ﬁbrosis. Heterotopic transplantation of small bowel resections in
mice was followed by a rapid and constant ﬁbrosis of the
intestinal wall. The method is based on a recently described rat
model of ﬁbrosis as a substantial advance in understanding the
formation of intestinal ﬁbrosis.16 Small bowel resections of donor
mice were implanted into subcutaneous pouches of recipients.
Grafts showed complete ﬁbrosis in a time-dependent manner
characterized by an increased deposition of collagen. EvG and
sirius red staining conﬁrmed signiﬁcantly increased collagen layer
thickness in transplants and revealed a diffuse network of ﬁbrils in
FIGURE 7. Increased pFAK after administration of pirfenidone compared to control in grafts from the heterotopic transplantation model. (A)
Western blotting (left) and densitometric analysis (right) showed signiﬁcant increase in the ratio pFAK/total FAK after treatment with pirfenidone
(**P , 0.01, n ¼ 4 for each column, error bars ¼ SEM). (B) a-SMA mRNA expression is signiﬁcantly decreased, whereas BCL-XL mRNA expression is
signiﬁcantly increased after treatment with pirfenidone compared to vehicle (*P , 0.05, n ¼ 9 each column, error bars ¼ SEM).
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the obliterated lumen. In addition, immunohistochemistry re-
vealed a time-dependent increase of TGF-b.
Fibrosis is traditionally viewed as the endpoint of a long-
term process consisting of a chronic response of the digestive
tract. Accordingly, intestinal ﬁbrosis is viewed as a slow,
unidirectional process,27 in which inﬂammation encourages local
ﬁbroblast to multiply and deposit extracellular matrix as part of
a wound-healing process. Although not necessarily incorrect,
based on our results, this view should be extended to the obser-
vation that ﬁbrosis could also be rapidly initiated and increased.
Recent studies also suggest ﬁbrogenesis as a very early process
associated with inﬂammation.28 Results from our own studies
support this hypothesis as rapid increase of collagen layer thick-
ness, fast development of occlusion, and rapid increase of TGF-
b in grafts can be determined shortly after transplantation.
The antiﬁbrotic effect of pirfenidone was successfully
tested both in vitro and in our new model of intestinal ﬁbrosis.
In in vitro experiments, we determined a signiﬁcant decrease in
TGF-b, COL1A1, MMP-9, and a-SMA mRNA expressions after
administration of pirfenidone in a dose-dependent manner com-
pared with vehicle. This shows that hallmarks of progressive
development of ﬁbrosis are decreased after treatment with pirfe-
nidone in intestinal ﬁbroblasts.
Studies concerning ﬁbroblasts of other tissues revealed that
pFAK is a central regulator of cell migration in health and
disease.29–32 FAK is a nonreceptor protein tyrosine kinase involved
in integrin-mediated control of cell behavior. The amount of FAK
protein phosphorylation is increased during cell migration.33 The
autophosphorylation of FAK at the tyrosine residue 397 is a marker
for the activation of FAK. Phosphorylation creates an SH2 binding
site for different signaling and adapter proteins.32,34 Migration of
colonic ﬁbroblasts is stimulated by growth factors like TGF-b,
platelet-derived growth factor (PDGF)-AB, insulin-like growth
factor (IGF)-I, and epidermal growth factor. Colonic ﬁbroblasts
also stimulate their own migration through an autocrine mecha-
nism.26 Migratory potential of colonic ﬁbroblasts from patients
with IBD is reduced compared with normal colonic ﬁbroblasts,
which is correlated with diminished FAK phosphorylation.35 In
contrast to TGF-b, FAK protein phosphorylation and BCL-XL
mRNA expression are increased after administration of pirfeni-
done in our studies. This suggests an increased migratory potential
and viability of cells and is conﬁrmative with results from the
performed wounding assay that revealed an advanced wound clo-
sure after treatment with pirfenidone. In our murine model of
intestinal ﬁbrosis, we determined a signiﬁcantly deceased collagen
layer thickness in harvested grafts from mice after administration
of oral pirfenidone in comparison to vehicle-treated mice. Further-
more, TGF-b expression on mRNA and protein level was signif-
icantly reduced by pirfenidone. Conﬁrmative to the in vitro
experiments, FAK protein phosphorylation and BCL-XL mRNA
expressions were increased after treatment with pirfenidone sug-
gesting an increased migratory potential and viability of cells in the
graft. Grafts from mice treated with pirfenidone showed
FIGURE 8. MMPs and proinﬂammatory cytokines are decreased after
administration of pirfenidone in grafts from the heterotopic trans-
plantation model. MMP-2, MMP-9, MMP-13, and TIMP-1 are decreased
after treatment with pirfenidone compared to vehicle (*P , 0.05,
Kruskal–Wallis one-way analysis of variance on ranks, all-pairwise
multiple comparison procedures (Holm–Sidak method), A). IL-1b, IL-6,
and MCP-1 are decreased after treatment with pirfenidone (B). LOXL-2,
COL1A1, and COL3A1 are decreased after treatment with pirfenidone
(C). N ¼ 13 to 15 for each column, error bars ¼ SD.
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a signiﬁcant decrease in a-SMA and MMP-9 mRNA expression
compared to vehicle. MMP-2, MMP-13, TIMP-1, IL-1b, IL-6,
MCP-1, and LOXL-2 mRNA expressions also were reduced.
Pirfenidone is known to exhibit antiﬁbrotic and anti-
inﬂammatory effects in a variety of organs by modulating various
genes known to be involved in wound healing and ﬁbrosis, including
TGF-b, MMP-2, and MMP-9.19,20,23,24,36 Graham and Diegelmann37
showed that TGF-b promotes collagen deposition by smooth muscle
cells isolated from CD tissue, a process that may play a signiﬁcant
role in stricture formation and ﬁbrosis in patients with CD. In addi-
tion, TGF-b is known to inhibit intestinal epithelial cell proliferation,
a process that may inhibit re-epithelialization after surface injury.38–40
The gelatinases (MMP-2 and MMP-9) degrade denatured collagen of
all types.41 MMP-2 and MMP-9 are upregulated in patients with IBD
in active ﬂares.42–45 MMP-2 is expressed in almost all tissues and is
markedly increased in IBD tissues.46 MMP-9 activity and protein
expression are upregulated during dextran sulphate sodium colitis,
and in normal colonic mucosa, the expression is absent.47
MMP-92/2 mice have signiﬁcantly less severe DSS-induced colitis
with reduced inﬂammation and mucosal injury.48
Thus, pirfenidone may be a new treatment option to prevent
ﬁbrogenesis and development of strictures in patients with IBD. In
patients with IPF after 72 weeks following daily pirfenidone
administration, following adverse effects could be detected with
an increased incidence: nausea, rash, dyspepsia, dizziness, vomit-
ing, photosensitivity reaction, anorexia, arthralgia, insomnia,
abdominal distention, decreased appetite, stomach discomfort,
weight reduction, abdominal pain, asthenia, pharyngolaryngeal
pain, pruritus, and hot ﬂush.17
The described heterotopic transplantation in mice will serve
as a new model to develop treatments targeted at intestinal ﬁbrosis
and provide the opportunity of using genetically altered animals.
Important aspects of human intestinal ﬁbrosis are reﬂected in our
model of heterotopic transplantation in mice. It may also be
instrumental in deciphering the formation of intestinal ﬁbrosis at
the molecular level. The utilization of our new in vivo heterotopic
transplant animal model of intestinal ﬁbrosis may ultimately lead
to novel interventions in the prevention of treatment of intestinal
ﬁbrosis. We were able to conﬁrm the postulated antiﬁbrotic
effects of pirfenidone. Thus, pirfenidone may be a new treatment
option to prevent intestinal ﬁbrosis formation in IBD.
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